In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11- 2933

M. A. Alaoui-Jamali, R. L. Schecter, Y. M. Rustum, M. G. Centurioni, S. Lehnert, G. Batist

Research output: Contribution to journalArticle

Abstract

The effectiveness of a calcium antagonist analog Ro11-2933 to modulate doxorubicin (DOX) response in DOX-sensitive (WT) and -resistant (DOXr, 200- fold) cell lines was investigated and compared to verapamil (VP) in vitro and in vivo in rats bearing mammary carcinoma using equivalent nontoxic doses. In vitro exposure to a nontoxic concentration of Ro11-2933 (2 μM) normalizes the DOX accumulation defect observed in DOXr cells, increases DOX-induced DNA single-strand breaks and effectively sensitizes DOXr cells to DOX. Ten μM VP was required to obtain an effect equivalent to that seen with 2 μM Ro11- 2933. Intravenous administration of DOX at 5 mg/kg to the rat bearing the DOXr tumors has no significant therapeutic effect on tumor growth (P > .5), whereas it was found effective in inhibiting the growth of WT tumors (P <.05). Ro11-2933 or VP administered alone has no significant effect on tumor growth as compared to a saline-treated group (P > .1). Combination of Ro11- 2933 with DOX effectively inhibits DOXr tumor growth as compared to DOX alone. Combination of DOX with VP was found less effective than Ro11-2933 and the results were not statistically significant from DOX treatment alone (P > .5). Our data demonstrate that Ro11-2933 is well tolerated after i.v. administration and an effective modulator of DOX resistance in a solid tumor model.

Original languageEnglish
Pages (from-to)1299-1304
Number of pages6
JournalJournal of Pharmacology and Experimental Therapeutics
Volume264
Issue number3
Publication statusPublished - 1993

Fingerprint

Tiapamil Hydrochloride
Doxorubicin
Verapamil
Neoplasms
Growth
Therapeutic Uses
Intravenous Administration

ASJC Scopus subject areas

  • Pharmacology

Cite this

Alaoui-Jamali, M. A., Schecter, R. L., Rustum, Y. M., Centurioni, M. G., Lehnert, S., & Batist, G. (1993). In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11- 2933. Journal of Pharmacology and Experimental Therapeutics, 264(3), 1299-1304.

In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11- 2933. / Alaoui-Jamali, M. A.; Schecter, R. L.; Rustum, Y. M.; Centurioni, M. G.; Lehnert, S.; Batist, G.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 264, No. 3, 1993, p. 1299-1304.

Research output: Contribution to journalArticle

Alaoui-Jamali, MA, Schecter, RL, Rustum, YM, Centurioni, MG, Lehnert, S & Batist, G 1993, 'In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11- 2933', Journal of Pharmacology and Experimental Therapeutics, vol. 264, no. 3, pp. 1299-1304.
Alaoui-Jamali MA, Schecter RL, Rustum YM, Centurioni MG, Lehnert S, Batist G. In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11- 2933. Journal of Pharmacology and Experimental Therapeutics. 1993;264(3):1299-1304.
Alaoui-Jamali, M. A. ; Schecter, R. L. ; Rustum, Y. M. ; Centurioni, M. G. ; Lehnert, S. ; Batist, G. / In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11- 2933. In: Journal of Pharmacology and Experimental Therapeutics. 1993 ; Vol. 264, No. 3. pp. 1299-1304.
@article{7cd73731bd394a38a0b065cf83bfaf4b,
title = "In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11- 2933",
abstract = "The effectiveness of a calcium antagonist analog Ro11-2933 to modulate doxorubicin (DOX) response in DOX-sensitive (WT) and -resistant (DOXr, 200- fold) cell lines was investigated and compared to verapamil (VP) in vitro and in vivo in rats bearing mammary carcinoma using equivalent nontoxic doses. In vitro exposure to a nontoxic concentration of Ro11-2933 (2 μM) normalizes the DOX accumulation defect observed in DOXr cells, increases DOX-induced DNA single-strand breaks and effectively sensitizes DOXr cells to DOX. Ten μM VP was required to obtain an effect equivalent to that seen with 2 μM Ro11- 2933. Intravenous administration of DOX at 5 mg/kg to the rat bearing the DOXr tumors has no significant therapeutic effect on tumor growth (P > .5), whereas it was found effective in inhibiting the growth of WT tumors (P <.05). Ro11-2933 or VP administered alone has no significant effect on tumor growth as compared to a saline-treated group (P > .1). Combination of Ro11- 2933 with DOX effectively inhibits DOXr tumor growth as compared to DOX alone. Combination of DOX with VP was found less effective than Ro11-2933 and the results were not statistically significant from DOX treatment alone (P > .5). Our data demonstrate that Ro11-2933 is well tolerated after i.v. administration and an effective modulator of DOX resistance in a solid tumor model.",
author = "Alaoui-Jamali, {M. A.} and Schecter, {R. L.} and Rustum, {Y. M.} and Centurioni, {M. G.} and S. Lehnert and G. Batist",
year = "1993",
language = "English",
volume = "264",
pages = "1299--1304",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11- 2933

AU - Alaoui-Jamali, M. A.

AU - Schecter, R. L.

AU - Rustum, Y. M.

AU - Centurioni, M. G.

AU - Lehnert, S.

AU - Batist, G.

PY - 1993

Y1 - 1993

N2 - The effectiveness of a calcium antagonist analog Ro11-2933 to modulate doxorubicin (DOX) response in DOX-sensitive (WT) and -resistant (DOXr, 200- fold) cell lines was investigated and compared to verapamil (VP) in vitro and in vivo in rats bearing mammary carcinoma using equivalent nontoxic doses. In vitro exposure to a nontoxic concentration of Ro11-2933 (2 μM) normalizes the DOX accumulation defect observed in DOXr cells, increases DOX-induced DNA single-strand breaks and effectively sensitizes DOXr cells to DOX. Ten μM VP was required to obtain an effect equivalent to that seen with 2 μM Ro11- 2933. Intravenous administration of DOX at 5 mg/kg to the rat bearing the DOXr tumors has no significant therapeutic effect on tumor growth (P > .5), whereas it was found effective in inhibiting the growth of WT tumors (P <.05). Ro11-2933 or VP administered alone has no significant effect on tumor growth as compared to a saline-treated group (P > .1). Combination of Ro11- 2933 with DOX effectively inhibits DOXr tumor growth as compared to DOX alone. Combination of DOX with VP was found less effective than Ro11-2933 and the results were not statistically significant from DOX treatment alone (P > .5). Our data demonstrate that Ro11-2933 is well tolerated after i.v. administration and an effective modulator of DOX resistance in a solid tumor model.

AB - The effectiveness of a calcium antagonist analog Ro11-2933 to modulate doxorubicin (DOX) response in DOX-sensitive (WT) and -resistant (DOXr, 200- fold) cell lines was investigated and compared to verapamil (VP) in vitro and in vivo in rats bearing mammary carcinoma using equivalent nontoxic doses. In vitro exposure to a nontoxic concentration of Ro11-2933 (2 μM) normalizes the DOX accumulation defect observed in DOXr cells, increases DOX-induced DNA single-strand breaks and effectively sensitizes DOXr cells to DOX. Ten μM VP was required to obtain an effect equivalent to that seen with 2 μM Ro11- 2933. Intravenous administration of DOX at 5 mg/kg to the rat bearing the DOXr tumors has no significant therapeutic effect on tumor growth (P > .5), whereas it was found effective in inhibiting the growth of WT tumors (P <.05). Ro11-2933 or VP administered alone has no significant effect on tumor growth as compared to a saline-treated group (P > .1). Combination of Ro11- 2933 with DOX effectively inhibits DOXr tumor growth as compared to DOX alone. Combination of DOX with VP was found less effective than Ro11-2933 and the results were not statistically significant from DOX treatment alone (P > .5). Our data demonstrate that Ro11-2933 is well tolerated after i.v. administration and an effective modulator of DOX resistance in a solid tumor model.

UR - http://www.scopus.com/inward/record.url?scp=0027507488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027507488&partnerID=8YFLogxK

M3 - Article

C2 - 8450465

AN - SCOPUS:0027507488

VL - 264

SP - 1299

EP - 1304

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -